References
- Quaranta D, Marra C, Zinno M et al. Presentation and validation of the Multiple Sclerosis Depression Rating Scale: a test specifically devised to investigate affective disorders in multiple sclerosis patients. Clin. Neuropsychol. 26(4), 571–587 (2012).
- Nyenhuis DL, Rao SM, Zajecka JM, Luchetta T, Bernardin L, Garron DC. Mood disturbance versus other symptoms of depression in multiple sclerosis. J. Int. Neuropsychol. Soc. 1(3), 291–296 (1995).
- Chang CH, Nyenhuis DL, Cella D, Luchetta T, Dineen K, Reder AT. Psychometric evaluation of the Chicago Multiscale Depression Inventory in multiple sclerosis patients. Mult. Scler. 9(2), 160–170 (2003).
- Patten SB, Fridhandler S, Beck CA, Metz LM. Depressive symptoms in a treated multiple sclerosis cohort. Mult. Scler. 9(6), 616–620 (2003).
- Kroenke K, Spitzer RL, Williams JB, Löwe B. The Patient Health Questionnaire Somatic, Anxiety, and Depressive Symptom Scales: a systematic review. Gen. Hosp. Psychiatry 32(4), 345–359 (2010).
- Hamilton M. Development of a rating scale for primary depressive illness. Br. J. Soc. Clin. Psychol. 6(4), 278–296 (1967).
- Potts MK, Daniels M, Burnam MA, Wells KB. A structured interview version of the Hamilton Depression Rating Scale: evidence of reliability and versatility of administration. J. Psychiatr. Res. 24(4), 335–350 (1990).
- Miller AH, Maletic V, Raison CL. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol. Psychiatry 65(9), 732–741 (2009).
- Zabad RK, Patten SB, Metz LM. The association of depression with disease course in multiple sclerosis. Neurology 64(2), 359–360 (2005).
- Musselman DL, Lawson DH, Gumnick JF et al. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N. Engl. J. Med. 344(13), 961–966 (2001).